7
1
↑0
↓7
—1
Evidence suggests Walking maydecreaseType 2 diabetes.
4 studies (8 claims)
Emerging evidence
Typical effective dose 75 (75–75) %across 1 dosed study
Study Claims
| Intervention | Direction | Endpoint | Type | Population | Dosage | Title |
|---|---|---|---|---|---|---|
| pedometer-based walking interventions | No effect - diabetes 0.75 (95% CI 0.42-1.36, p = 0.34) | diabetes | Human | intervention participants versus controls | Not specified (pedometer-based walking interventions). | Effect of pedometer-based walking interventions on long-term health outcomes: Prospective 4-year follow-up of two randomised controlled trials using routine primary care data.cited 33× |
| running and walking dose (metabolic equivalent hours/day [MET-h/d]) | Decreases - decreased | fatal diabetes risk | Human | hypercholesterolemic patients | 1.8 to 3.6 MET-h/d and ≥3.6 MET-h/d. | Incident diabetes mellitus, hypertension, and cardiovascular disease risk in exercising hypercholesterolemic patients.cited 9× |
| running and walking dose (metabolic equivalent hours/day [MET-h/d]) | Decreases - decreased | nonfatal diabetes risk | Human | hypercholesterolemic patients | 1.8 to 3.6 MET-h/d and ≥3.6 MET-h/d. | Incident diabetes mellitus, hypertension, and cardiovascular disease risk in exercising hypercholesterolemic patients.cited 9× |
| ≥3.6 MET-h/d of running and walking | Decreases - decreased | fatal diabetes risk | Human | hypercholesterolemic patients | 1.8 to 3.6 MET-h/d and ≥3.6 MET-h/d. | Incident diabetes mellitus, hypertension, and cardiovascular disease risk in exercising hypercholesterolemic patients.cited 9× |
| ≥3.6 MET-h/d of running and walking | Decreases - decreased | nonfatal diabetes risk | Human | hypercholesterolemic patients | 1.8 to 3.6 MET-h/d and ≥3.6 MET-h/d. | Incident diabetes mellitus, hypertension, and cardiovascular disease risk in exercising hypercholesterolemic patients.cited 9× |
| 1.8 to 3.6 MET-h/d of running and walking | Decreases - decreased | fatal diabetes risk | Human | hypercholesterolemic patients | 1.8 to 3.6 MET-h/d and ≥3.6 MET-h/d. | Incident diabetes mellitus, hypertension, and cardiovascular disease risk in exercising hypercholesterolemic patients.cited 9× |
| 1.8 to 3.6 MET-h/d of running and walking | Decreases - decreased | nonfatal diabetes risk | Human | hypercholesterolemic patients | 1.8 to 3.6 MET-h/d and ≥3.6 MET-h/d. | Incident diabetes mellitus, hypertension, and cardiovascular disease risk in exercising hypercholesterolemic patients.cited 9× |
| postmeal walking (PMW, breaking up exercise into short bouts after meals) | No effect - is an effective and feasible alternative to continuous walking | management of gestational diabetes | Human | women with gestational diabetes | Postmeal walking: 10 minutes after breakfast, lunch, and dinner; continuous walking: 30 minutes. | Three short postmeal walks as an alternate therapy to continuous walking for women with gestational diabetes.cited 5× |
| walking ∼18.2 km per week | Decreases - may be nearly as effective as | preventing the progression to diabetes | Human | prediabetic individuals | 42 kJ/kg body weight/week (~16 km/week) or 67 kJ/kg body weight/week (~22.3 km/week), performed at moderate (50% VO2max) or vigorous (75% VO2max) intensity. | Effects of exercise training alone vs a combined exercise and nutritional lifestyle intervention on glucose homeostasis in prediabetic individuals: a randomised controlled trial.cited 86× |